Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation

A method of treating a CCR2-mediated condition or disease, comprising administering to a subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof:

• where:
• R1 and R2 are each independently hydrogen, halogen, C1-8 alkyl, —CN, or C1-8 haloalkyl, provided that at least one of R1 or R2 is other than hydrogen;
• each R3 is independently hydrogen;
• R4 is hydrogen;
• R5 is halogen or C1-8 alkyl;
• R6 is hydrogen;
• X1 is CR7, N or NO;
• X2 and X4 are N or NO;
• X3 is CR7;
• X6 and X7 are each independently selected from CR7, N, and NO;
• each R7 is independently selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted C2-8 alkenyl, substituted or unsubstituted C2-8 alkynyl, —CN, ═O, —NO2, —OR8, —OC(O)R8, —CO2R8, —C(O)R8, —C(O)NR9R8, —OC(O)NR9R8, —NR10C(O)R8, —NR10C(O)NR9R8, —NR9R8, —NR10CO2R8, —SR8, —S(O)R8, —S(O)2R8, —S(O)2NR9R8, —NR10S(O)2R8, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl and substituted or unsubstituted 3- to 10-membered heterocyclyl;
• each occurrence of R8, R9, and R10 is independently selected from the group consisting of hydrogen, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, aryl, or heteroaryl;
• or R9 and R8 or R10 and R8, together with the atom(s) to which they are attached, form a substituted or unsubstituted 5-, 6-, or 7-membered ring;
• and
• R11 is selected from the group consisting of hydrogen, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl and substituted or unsubstituted 3- to 10-membered heterocycle;
• wherein the CCR2-mediated condition or disease is selected from psoriasis, graft-versus-host disease, and transplantation rejection.